Get started
Award

P50-CA062924

Funded outputs count: 956
Funder award ID: P50-CA062924
OpenAlex ID: G1324540468
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial
2026 · Hejia Henry Wang, Amanda L. Huff, et al. · Nature Communications · 1
PDF
Enterotoxigenic Bacteroides fragilis Induces Host Genotype-Specific Colonic Epithelial and Immune Responses in Mice
2026 · Taylor Southward, Yongbao Zhuang, et al. · The Journal of Infectious Diseases
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
2026 · Amanda L. Huff, S. Daniel Haldar, et al. · Nature Communications · 22
PDF
Comparative assessment of physiochemical metrics for the clustering of adaptive immune receptor repertoires
2025 · Alexander A Girgis, Amanda L Huff, et al. · Nucleic Acids Research
PDF
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
2025 · Ting Zhang, Xing Hua, et al. · JNCI Journal of the National Cancer Institute · 3
PDF
Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
2025 · Dorothy Hallberg, Alice C. Eastman, et al. · Cancer Research Communications · 2
PDF
Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment
2025 · Dimitrios N. Sidiropoulos, Sarah M. Shin, et al. · Cancer Immunology Research · 16
Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories
2025 · Jeanette A.I. Johnson, Daniel R. Bergman, et al. · Cell · 66
Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia
2025 · Melissa R. Lyman, Jacob T. Mitchell, et al. · JCI Insight · 14
PDF
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
2025 · Eric S. Christenson, Won Jin Ho, et al. · Clinical Cancer Research · 15
P4HA1 Mediates Hypoxia-Induced Invasion in Human Pancreatic Cancer Organoids
2025 · Bernat Navarro-Serer, Maria F. Wissler, et al. · Cancer Research Communications · 7
Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes
2025 · Dimitrios Mathios, Noushin Niknafs, et al. · Cancer Discovery · 13
PDF
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
2025 · Chester Kao, Soren Charmsaz, et al. · Nature Communications · 35
PDF
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
2025 · Mari Nakazawa, Soren Charmsaz, et al. · Cancer Immunology Research · 7
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
2025 · Jeanne Tie, Yuxuan Wang, et al. · Nature Medicine · 137
Clinical development of immuno-oncology therapeutics
2025 · Jianxin Wang, Qi Chen, et al. · Cancer Letters · 56
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments
2025 · Sophia Y. Chen, Heng-Chung Kung, et al. · Experimental Hematology and Oncology · 8
PDF
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
2025 · Nan Niu, Keyu Li, et al. · Biomarker Research · 8
PDF
Comparison of Shared Class I HLA-Bound Noncanonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma
2024 · Tengyi Zhang, Betul Celiker, et al. · Clinical Cancer Research · 2
PDF
Islands of genomic stability in the face of genetically unstable metastatic cancer
2024 · Kirsten Bowland, Jiaying Lai, et al. · PLoS ONE · 2
PDF
CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial
2024 · Janelle M. Montagne, Jacob T. Mitchell, et al. · iScience · 15
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
2024 · Daniel J. Zabransky, Emma Kartalia, et al. · Hepatology · 16
PDF
SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors
2024 · Theron Palmer, Michael D Kessler, et al. · Cancer Research Communications · 11
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
2024 · Daniel H. Shu, Won Jin Ho, et al. · Nature Immunology · 129
PDF
Cancer treatment monitoring using cell-free DNA fragmentomes
2024 · Iris van ’t Erve, Bahar Alipanahi, et al. · Nature Communications · 51
PDF
Year
Topic